RVMD vs TYRA
RVMD: A precision oncology biotech in clinical development stages, pursuing targeted cancer therapies with no approved products yet but backed by substantial capital. TYRA: Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly targeting FGFR-driven diseases.
Side-by-side fundamentals
| Metric | RVMD | TYRA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $183.03 | $30.59 | |
| Market cap as of 2026-07-23 | $39.0B | $1.8B | |
| PEG as of 2026-07-23 | -0.34 | -0.44 | TYRA lower |
| Net margin as of 2026-07-23 | -2833.9% | n/a | |
| Operating margin as of 2026-07-23 | -3145.0% | n/a | |
| ROE as of 2026-07-23 | -54.1% | -42.7% | TYRA higher |
| ROA as of 2026-07-23 | -39.1% | -39.8% | RVMD higher |
| Debt / equity as of 2026-07-23 | 0.19 | 0.00 | TYRA lower |
| Beta as of 2026-07-23 | 1.41 | 0.75 | |
| 1-year return as of 2026-07-22 close | +378.3% | +200.2% | RVMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.